Tag: SLEEP 2025

All

Dentists and sleep physicians are compressing treatment timelines from months to weeks, without compromising outcomes.

As the first orexin-2 receptor agonist for narcolepsy nears FDA approval, a preclinical compound shows promise for its higher potency.

Five individuals have been selected as the 2025 AASM award recipients for their outstanding contributions to the field of sleep medicine.

Panthera Dental’s abstracts were accepted for poster presentation at the 2025 AADSM annual meeting and poster and oral presentation at SLEEP 2025.